SCHEMBL3606203

SCHEMBL3606203

CN(CCCNC(=O)Cn1ccc2cccc(-c3ccc(F)cc3)c21)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 6/20 0.43
TP53 P04637 4/20 0.43
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 3/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 4/20 0.38
HTT P42858 1/20 0.38
GRIN2B Q13224 1/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
KCNA3 P22001 1/20 0.37
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608258 0.95 GAA (0.43) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3594706 0.87 GAA (0.42) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3597285 0.87 MAPT (0.46) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3605624 0.86 GAA (0.41) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3605991 0.86 GAA (0.44) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3608184 0.86 KMT2A (0.43) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3605919 0.84 MAPT (0.40) CYP3A4MAPTTP53KMT2AKDM4E
SCHEMBL3589650 0.84 TSHR (0.41) CYP2D6CYP3A4MAPTTP53KMT2A
SCHEMBL3606204 0.83 GRIN2B (0.41) CYP2D6MAPTKMT2AKDM4EALDH1A1
SCHEMBL3589634 0.82 GAA (0.38) CYP2D6CYP3A4MAPTTP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 CYP2D6 4288/4885CYP3A4 4506/4885MAPT 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.